Turmeric and Curcumin on Sebum Production

Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Feb 23, 2017

Keywords

ClinConnect Summary

Turmeric extracts and curcumin have been shown to be safe, even at high doses without significant side-effects. Previous clinical studies in other inflammatory skin diseases have shown that a dosage of curcumin at 6,000 mg daily was effective while lower doses were not. In a human phase I clinical trial examining the effects of high dose curcumin in preventing premalignant lesions, even curcumin doses as high as 8,000 mg/day resulted in no toxic effects after 3 months. This study will involve participant ingestion of 6,000 mg/day of turmeric or curcumin to assess how this affects their sebu...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 to 50 years of age, and
• • 2. Subject must be able to read and comprehend study procedures and consent forms.
• Exclusion Criteria:
• • 1. Subject should be generally healthy and have no smoking history in the past one year, and must have no history of diabetes, metabolic syndrome, known cardiovascular disease, malignancy, kidney disease, or chronic steroid use.
• • 2. Those who used topical medications in the past two weeks or systemic antibiotics or oral probiotics within one month of starting the study.
• • 3. Subjects who are postmenopausal
• • 4. Those who are pregnant or breastfeeding.
• • 5. Those that are prisoners or cognitively impaired.
• • 6. Those who have a known allergy to black pepper should not participate in this clinical trial, since one of the treatments consists of tablets containing a small amount (1.25mg/tablet) of black pepper.
• • 7. Those that are taking angiotensin converting enzyme inhibitor medications or angiotensin receptor blocker medications for any reason.